GH Research PLC

GH Research PLC reported a net loss of $15.1 million for the second quarter of 2026 and $34.1 million for the first six months of the year, reflecting increased research and development activities. The company maintained a strong liquidity position with $345.1 million in cash and cash equivalents as of June 30, 2026, bolstered by $111.2 million in net proceeds from an April 2026 share offering. Operationally, GH Research achieved significant milestones, including FDA alignment on Phase 3 plans for GH001, completion of two Phase 1 trials, and the grant of a new U.S. patent for its mebufotenin therapies.

GH Research PLC announced that its annual general meeting was held on June 25, 2026. At the meeting, shareholders approved all resolutions recommended by the company's board of directors. Key approvals included the re-election of four directors and the ratification of PricewaterhouseCoopers Ireland as the independent auditors for the fiscal year ending December 31, 2026.

GH Research PLC announced the publication of full Phase 2a trial results for inhaled mebufotenin (GH001) in postpartum depression (PPD), showing rapid and sustained remission in all patients. The trial met its primary endpoint with a significant reduction in MADRS scores and demonstrated improved maternal functioning. Additionally, the company announced the acceptance of two oral presentations at CINP 2026, which will present data from its Phase 2b trial of GH001 in treatment-resistant depression (TRD).

GH Research PLC presented positive Phase 2b clinical trial results for its investigational drug GH001 in treatment-resistant depression (TRD) at the ASCP Annual Meeting. The data showed GH001 achieved rapid and sustained improvements in anhedonia, significantly reducing MADRS anhedonia factor scores by -9.9 points versus placebo at Day 8. Importantly, GH001's efficacy was independent of prior antidepressant treatment failures, maintaining consistent remission rates of 54-64% at Day 8 across subgroups. The trial also demonstrated significant improvements in overall illness severity, anxiety, and quality of life, with these beneficial effects sustained through a 6-month open-label extension.

GH Research PLC has entered into an At-the-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated. This agreement allows the company to offer and sell up to $200 million of its ordinary shares from time to time through Stifel, acting as a sales agent or principal. The offering has been registered under the Securities Act.

GH Research PLC reported a net loss of $19.0 million, or $0.31 per share, for the first quarter of 2026, an increase from $10.8 million loss in Q1 2025, driven by higher R&D and G&A expenses. The company ended the quarter with $267.3 million in cash, cash equivalents, and marketable securities, further bolstered by $111.2 million in net proceeds from an underwritten offering in April 2026. Key business updates include the publication of Phase 2b TRD trial results, completion of studies for the global Phase 3 pivotal program of GH001, and completion of a US IND-opening study.

GH Research PLC announced its attendance at the American Psychiatric Association Annual Meeting. The event is scheduled to occur in San Francisco, California, from May 16 to May 20, 2026. This participation provides an opportunity for the company to engage with the psychiatric community.

GH Research PLC announced the completion of an underwritten offering, selling 6,527,779 ordinary shares at $18.00 per share. This offering generated approximately $117.5 million in gross proceeds, with estimated net proceeds of $111.2 million. The company intends to use these funds to strategically invest in research, clinical and technical development of current and additional product candidates, pre-commercialization activities, working capital, capital expenditures, and general corporate purposes.

GH Research PLC announced the pricing of an underwritten offering of 6,527,779 ordinary shares at $18.00 per share, aiming to raise approximately $117.5 million in gross proceeds. All shares are being offered by the company, with the offering expected to close on April 30, 2026. The offering saw participation from Lynx1 Capital Management, Deep Track Capital, and Foresite Capital, with Stifel, Cantor, and RBC Capital Markets acting as joint book-running managers.